ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00908154
Recruitment Status : Completed
First Posted : May 25, 2009
Last Update Posted : October 30, 2017
Sponsor:
Information provided by (Responsible Party):
Biogen

Brief Summary:

GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models.

This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses of GSK1014802 administered for up to 28 days in healthy male or female subjects. In addition, the effect of food on the pharmacokinetics of GSK1014802 will be investigated.


Condition or disease Intervention/treatment Phase
Bipolar Depression Bipolar Disorder Drug: Placebo Drug: GSK1014802 Phase 1

Detailed Description:
This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers
Actual Study Start Date : May 31, 2008
Actual Primary Completion Date : December 31, 2008
Actual Study Completion Date : December 31, 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Arm Intervention/treatment
Cohort 1 Drug: Placebo
Tablets to match GSK1014802

Drug: GSK1014802
Sodium channel blocker
Other Name: BIIB074 and CNV1014802

Cohort 4 Drug: Placebo
Tablets to match GSK1014802

Drug: GSK1014802
Sodium channel blocker
Other Name: BIIB074 and CNV1014802

Cohort 3 Drug: Placebo
Tablets to match GSK1014802

Drug: GSK1014802
Sodium channel blocker
Other Name: BIIB074 and CNV1014802

Cohort 2 Drug: Placebo
Tablets to match GSK1014802

Drug: GSK1014802
Sodium channel blocker
Other Name: BIIB074 and CNV1014802




Primary Outcome Measures :
  1. Safety and tolerability will be evaluated by monitoring AEs and concomitant medication, ECG, Lead II monitoring, Holter monitoring, vital signs, and laboratory parameters. [ Time Frame: 14-28 days ]
  2. Blood concentrations of GSK1014802 following a single oral dose of GSK1014802. [ Time Frame: 1 day ]
  3. Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily or twice daily and their relationship with the GSK1014802 exposure after a single dose. [ Time Frame: 14-28 days ]
  4. Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily with or without food. [ Time Frame: 14-28 days ]

Secondary Outcome Measures :
  1. Bond-Lader VAS scale [ Time Frame: 14-28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.

    • Male or female (of non-child bearing potential) subjects aged between 18 and 55 years.
    • A female subject is eligible to participate if she is of non-childbearing potential.
    • Male subjects must agree to use an acceptable form of contraception.
    • Body weight ≥ 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive)
    • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
    • QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

Exclusion Criteria:

  • The subject has a positive pre-study drug/alcohol screen.

    • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
    • A positive test for HIV antibody.
    • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females).
    • Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s).
    • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives (60 h) or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
    • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
    • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
    • Pregnant females.
    • Lactating females.
    • Unwillingness or inability to follow the procedures outlined in the protocol.
    • History of sensitivity to heparin or heparin-induced thrombocytopenia.
    • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
    • . Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
    • History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908154


Locations
United Kingdom
GSK Investigational Site
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Biogen
Investigators
Study Director: Biogen Medical Director Biogen

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT00908154     History of Changes
Other Study ID Numbers: 107727
SCB107727
First Posted: May 25, 2009    Key Record Dates
Last Update Posted: October 30, 2017
Last Verified: October 2017

Keywords provided by Biogen:
sodium channel blocker
bipolar disorder
repeat dose

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Sodium Channel Blockers
Diuretics, Potassium Sparing
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs